Aprea Strengthens its Board
News Jan 21, 2014
Aprea AB has announced that Bernd R. Seizinger has been elected as a new member of the board. Bernd R. Seizinger, M.D., Ph.D., is Chairman of Opsona Therapeutics Ltd. and former Vice President, Oncology Drug Discovery at Bristol-Myers Squibb, Associate Professor of Neuroscience at Harvard Medical School and Associate Geneticist and Director of the Molecular Neuro-Oncology Laboratory at Massachusetts General Hospital in Boston, MA, USA.
“We are pleased to welcome Dr. Seizinger to the board”, says Torbjörn Bjerke, Chairman of Aprea AB. “His extensive research and clinical development experience within oncology from the pharmaceutical and biotechnology industries will be a great benefit to the company as we move forward.”
As biotech and pharma senior executive, Dr. Seizinger has held a number of positions such as President & CEO of oncology drug discovery and clinical development company GPC Biotech (Munich, Boston, Princeton, Houston), Vice-President Oncology Drug Discovery at Bristol-Myers Squibb (Princeton), Executive Vice President and Chief Scientific Officer at Genome Therapeutics (Boston), as well as Executive Chairman/Interim CEO at Opsona Ltd. (Dublin).
In addition to his current Board memberships at Opsona Ltd., Agennix AG, and TriMod Ltd., Dr. Seizinger previously held Board memberships at Altana Pharma AG, Santhera Pharmaceuticals, BioXell Spa, and Cytovia Inc.
Dr. Seizinger has authored more than 100 publications and has been the recipient of numerous scientific awards, including the Otto-Hahn-Medal of the Max-Planck-Society, the Wilson S. Stone Award for Cancer Research (U.S), and the von Recklinghausen Award by the U.S. National Neurofibromatosis Foundation.
High Fruit and Veg Consumption May Reduce Breast Cancer RiskNews
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers from Harvard T.H. Chan School of Public Health.READ MORE
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
Why Might Super-Tasters be at Higher Cancer Risk?News
High bitter-taste sensitivity is associated with a significantly increased risk of cancer in older British women, according to researchers who conducted a unique study of 5,500 women whose diet, lifestyle and health has been tracked for about 20 years.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018